CD-19 targeting ADC program (Immunomedics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCD-19 targeting ADC program (Immunomedics)

Drug Alias NamehA19-SN-38 conjugate (Immunomedics)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionDNA topoisomerase I inhibitorsB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19DNA topoisomerase I

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesImmunomedics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunomedics Inc

Active IndicationsN/A

Inactive IndicationsHematologic Neoplasms

Other Information

ATC CodeN/A